Antiretroviral therapy coverage in Singapore
Singapore: Antiretroviral therapy coverage was 86.0% in 2023. ◆ Volatile
Antiretroviral therapy coverage in Singapore, 2000–2023
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of people living with HIV.
Analysis
In 2023, antiretroviral therapy coverage in Singapore stood at 86.0%. That is the highest value across all 24 years on record.
That represents a change of up 1.2% on the previous year and up 30.3% over ten years.
Over the whole period, antiretroviral therapy coverage in Singapore peaked at 86.0% in 2023 and was at its lowest, 8.0%, in 2000.
Singapore ranks 33rd of 143 countries on this measure, in the top quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage in Singapore, year by year
| Year | % of people living with HIV | Change |
|---|---|---|
| 2000 | 8.0% | — |
| 2001 | 8.0% | +0.0% |
| 2002 | 9.0% | +12.5% |
| 2003 | 10.0% | +11.1% |
| 2004 | 10.0% | +0.0% |
| 2005 | 14.0% | +40.0% |
| 2006 | 20.0% | +42.9% |
| 2007 | 28.0% | +40.0% |
| 2008 | 36.0% | +28.6% |
| 2009 | 46.0% | +27.8% |
| 2010 | 50.0% | +8.7% |
| 2011 | 56.0% | +12.0% |
| 2012 | 61.0% | +8.9% |
| 2013 | 66.0% | +8.2% |
| 2014 | 72.0% | +9.1% |
| 2015 | 75.0% | +4.2% |
| 2016 | 76.0% | +1.3% |
| 2017 | 80.0% | +5.3% |
| 2018 | 80.0% | +0.0% |
| 2019 | 83.0% | +3.8% |
| 2020 | 85.0% | +2.4% |
| 2021 | 84.0% | -1.2% |
| 2022 | 85.0% | +1.2% |
| 2023 | 86.0% | +1.2% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 18.9% | 8.0% | 46.0% | 10 |
| 2010s | 69.9% | 50.0% | 83.0% | 10 |
| 2020s | 85.0% | 84.0% | 86.0% | 4 |
Countries ranked near Singapore
- 33 Azerbaijan 86.0% compare
- 33 Italy 86.0% compare
- 33 Liberia 86.0% compare
- 33 Sierra Leone 86.0% compare
- 33 Slovenia 86.0% compare
More health data for Singapore
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.5225 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,924 deaths per 1,000 people (2090)
- Number of infants who die before age 1 13 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2024)
- Population ages 00-04, female, annual growth rate 1.93 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0196 units per person (2025)
- Population ages 00-04, male, annual growth rate 2.52 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is antiretroviral therapy coverage in Singapore?
- Antiretroviral therapy coverage in Singapore was 86.0% in 2023, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage recorded in Singapore?
- The highest recorded value was 86.0% in 2023.
- What is the lowest antiretroviral therapy coverage recorded in Singapore?
- The lowest recorded value was 8.0% in 2000.
- How does Singapore rank for antiretroviral therapy coverage?
- Singapore ranks 33rd out of 143 countries with data for 2023.
- Is antiretroviral therapy coverage rising or falling in Singapore?
- Over the last ten years it is up 30.3%. The long-run trend across the full record is volatile.
- Where does this Singapore data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage (% of people living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 24 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.